OTC NASAL DECONGESTANT FINAL MONOGRAPH IS DUE OUT IN JUNE 1989
Executive Summary
OTC NASAL DECONGESTANT FINAL MONOGRAPH IS DUE OUT IN JUNE 1989, according to FDA's agenda for pending regulations, published in the April 24 Federal Register. The decongestant monograph, published as a proposed rule in January 1985, is one of the last three remaining documents in the cough/cold rulemaking; final rules are still pending for antitussives and cough/cold combinations. Final monographs are also anticipated in June for skin protectants and aphrodisiacs. Other OTC rulemakings expected during the year include: the proposed rule for topical antifungals, in June; revisions to the antiseptic first aid and antiseptic professional use monographs, in September; and amendments to the proposed rulemakings for external analgesics and skin protectants relating to poison ivy, in June. FDA has set a target date in June for its proposed regulations implementing Title I of the Waxman/Hatch Patent Term Restoration Act. The regs were signed off by FDA Commissioner Young in March and sent directly to the Office of Management and Budget, bypassing review by HHS ("The Pink Sheet" March 20, p. 4). The long awaited orphan drug regs are also planned for a summer release, with a July publication date for the proposed rule designated in the regulatory agenda. Among the other anticipated regs are proposed rules specifying any needed changes to the existing Good Manufacturing Practice (GMP) standards for finished pharmaceuticals and blood/blood components, scheduled for November, and the proposed rule for biological product adverse reporting requirements, scheduled for September.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth